Successful Treatment of Psoriasis Combined with Bullous Pemphigoid with Dupilumab: A Case Report

被引:4
|
作者
Liu, Jing-Hua [1 ,2 ]
Gao, Qian [1 ]
Ma, Wen-Yi [1 ]
Cheng, Zi-Lin [1 ]
Luo, Na-Na [1 ]
Hao, Ping-Sheng [1 ,3 ]
机构
[1] Hosp Chengdu Univ Tradit Chinese Med, Dept Dermatol, Chengdu, Sichuan, Peoples R China
[2] Dalian Dermatosis Hosp, Dalian, Liaoning, Peoples R China
[3] Hosp Chengdu Univ Tradit Chinese Med, 39 Shi er qiao Rd, Chengdu, Sichuan Provinc, Peoples R China
来源
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY | 2023年 / 16卷
关键词
autoimmune bullous diseases; dupilumab; biologics; comorbidity; Chinese herbal compounds; USTEKINUMAB; THERAPY; PATIENT;
D O I
10.2147/CCID.S415019
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Psoriasis is an immune-mediated chronic inflammatory disease that can be combined with complications such as diabetes, cardiovascular disease, obesity, and kidney disease. The comorbidity of psoriasis with autoimmune bullous diseases (AIBD) has been reported previously in several cases, the most frequent of which is bullous pemphigoid (BP). The underlying mechanisms of psoriasis with BP are not clear and there are no uniform treatment criteria. Based on previous case reports, the coexistence of psoriasis and BP may be related to inflammatory activity, medications, phototherapy, and infection. We report a case of a psoriasis patient who developed BP after taking Chinese herbal compounds and was successfully treated with dupilumab, which is the first reported case of applying dupilumab to treat psoriasis with BP comorbidities.
引用
收藏
页码:1583 / 1587
页数:5
相关论文
共 50 条
  • [21] Case Report: Coexistence of bullous pemphigoid and psoriasis: Therapeutic challenge and IL17A-targeted parallel treatment strategy
    Drenovska, Kossara
    Valeva, Elia
    Shahid, Martin
    Vassileva, Snejina
    FRONTIERS IN MEDICINE, 2023, 10
  • [22] Esophageal involvement in Bullous pemphigoid: Case report
    Zahraoui, Salma
    Benjelloun, Najlae
    Salihoun, Mouna
    Bouhamou, Fatiha
    Acharki, Mohammed
    Serraj, Ilham
    Kabbaj, Nawal
    SAGE OPEN MEDICAL CASE REPORTS, 2024, 12
  • [23] The treatment of refractory atypical bullous pemphigoid with generalized eczema and intense pruritus with dupilumab
    Li, Wei
    Cai, Suiqing
    Man, Xiaoyong
    DERMATOLOGIC THERAPY, 2022, 35 (02)
  • [24] Bullous pemphigoid induced by ustekinumab: a case report
    Marin, Marta
    Alzueta, Natalia
    Castresana, Marta
    Gascon, Ana
    Pio, Maria
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2021, 28 (01) : 47 - 49
  • [25] Biological treatment for bullous pemphigoid
    Oren-Shabtai, Meital
    Mimouni, Daniel
    Nosrati, Adi
    Atzmony, Lihi
    Kaplan, Baruch
    Barzilai, Aviv
    Baum, Sharon
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [26] Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?
    Russo, Roberto
    Capurro, Niccolo
    Cozzani, Emanuele
    Parodi, Aurora
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (12)
  • [27] Pathogenicity of IgE in autoimmunity: Successful treatment of bullous pemphigoid with omalizumab
    Fairley, Janet A.
    Baum, Christian L.
    Brandt, Debra S.
    Messingham, Kelly A. N.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (03) : 704 - 705
  • [28] Serum inflammatory biomarkers associated with disease severity and response to dupilumab treatment in bullous pemphigoid: A cluster analysis
    Li, Jiaqi
    Chen, Xixue
    Zhu, Xuejun
    Shang, Panpan
    Wang, Mingyue
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2024, 116 (01) : 24 - 33
  • [29] Successful treatment of dupilumab in Kimura disease independent of IgE: A case report with literature review
    Yang, Boyun
    Yu, Hanxiao
    Jia, Minyue
    Yao, Wo
    Diao, Ran
    Li, Bohui
    Wang, Yongfang
    Li, Ting
    Ge, Liuya
    Wang, Huiying
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [30] Pustular Psoriasis Induced by Dupilumab: A Case Report
    Liu, Yuetong
    Liu, Lanxin
    Zhou, Hongmei
    Chen, Guangfang
    Wen, Changhui
    Wu, Ran
    JOURNAL OF INFLAMMATION RESEARCH, 2024, 17 : 6389 - 6394